Skip to main content
Home > Week in Review > Sales & Marketing

Chronological Index of : Sales and Marketing

 Current Issue
  • Exact Sciences, Tufts Health Plan sales and marketing update

    Exact Sciences Corp. (NASDAQ:EXAS), Madison, Wis. Tufts Health Plan, Watertown, Mass. Business: Cancer Tufts will cover Exacts Cologuard to screen for colon cancer. The test is available to members ages 50 and older who…

    Published on 4/13/2015
  • Merck sales and marketing update

    Merck & Co. Inc. (NYSE:MRK), Whitehouse Station, N.J. Business: Infectious Merck launched Gardasil 9 in Canada to prevent cancers caused by HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58 in females ages 9-45 and males …

    Published on 4/13/2015
  • Omeros sales and marketing update

    Omeros Corp. (NASDAQ:OMER), Seattle, Wash. Business: Ophthalmic Omeros launched Omidria in the U.S. to maintain intraoperative mydriasis (pupil size) by preventing intraoperative miosis and to reduce postoperative …

    Published on 4/13/2015
  • Aetna, U.S. Department of Health and Human Services sales and marketing update

    Aetna Inc. (NYSE:AET), Hartford, Conn. U.S. Department of Health and Human Services, Washington, D.C. Business: Infectious Aetna said its CoventryOne unit will move most of the HIV drugs in its Florida formulary from …

    Published on 4/6/2015
  • Agena Bioscience sales and marketing update

    Agena Bioscience Inc., San Diego, Calif. Business: Pharmacogenetics Agena launched the research use-only LungFUSION panel worldwide to identify anaplastic lymphoma kinase (ALK), ret proto-oncogene (RET) and c-ros proto-…

    Published on 4/6/2015
  • Dendreon sales and marketing update

    Dendreon Corp. (Pink:DNDNQ), Seattle, Wash. Business: Cancer The U.K.s NICE issued final guidance recommending against the use of Dendreons Provenge sipuleucel-T to treat asymptomatic or minimally symptomatic metastatic…

    Published on 4/6/2015
  • Hospira sales and marketing update

    Hospira Inc. (NYSE:HSP), Lake Forest, Ill. Business: Autoimmune, Biosimilars Hospira launched Inflectra infliximab in Canada to treat rheumatoid arthritis (RA), psoriatic arthritis, ankylosing spondylitis and plaque …

    Published on 4/6/2015
  • Sanofi sales and marketing update

    Sanofi (Euronext:SAN; NYSE:SNY), Paris, France Business: Endocrine/Metabolic Sanofi launched once-daily Toujeo insulin glargine in the U.S. to improve glycemic control in Type I and II diabetics. The product is a 300 …

    Published on 4/6/2015
  • Shire sales and marketing update

    Shire plc (LSE:SHP; NASDAQ:SHPG), Dublin, Ireland Business: Endocrine/Metabolic Shire launched Natpara in the U.S. as an adjunct to calcium and vitamin D to control hypocalcemia in patients with hypoparathyroidism. The …

    Published on 4/6/2015
  • Alfa Wassermann, Norgine sales and marketing update

    Alfa Wassermann S.p.A., Bologna, Italy Norgine B.V., Amsterdam, the Netherlands Business: Hepatic The U.K.s NICE issued final guidance recommending 550 mg Targaxan rifaximin from Norgine to prevent recurrence of …

    Published on 3/30/2015
  • Bayer A sales and marketing update

    Bayer AG (Xetra:BAYN), Leverkusen, Germany Business: Cardiovascular The U.K.s NICE issued final guidance recommending use of Xarelto rivaroxaban from Bayer in combination with aspirin plus clopidogrel or aspirin alone …

    Published on 3/30/2015
  • Boehringer Ingelheim, Eli Lilly sales and marketing update

    Boehringer Ingelheim GmbH, Ingelheim, Germany Eli Lilly and Co. (NYSE:LLY), Indianapolis, Ind. Business: Endocrine/Metabolic The U.K.s NICE issued final guidance recommending Jardiance empagliflozin from Boehringer …

    Published on 3/30/2015
  • Celgene Corp sales and marketing update

    Celgene Corp. (NASDAQ:CELG), Summit, N.J. Business: Cancer The U.K.s NICE issued final guidance recommending against use of Imnovid pomalidomide from Celgene in combination with dexamethasone to treat relapsed and …

    Published on 3/30/2015
  • Eisai sales and marketing update

    Eisai Co. Ltd. (Tokyo:4523), Tokyo, Japan Business: Cancer Eisais Eisai Inc. subsidiary launched Lenvima lenvatinib in the U.S. to treat progressive, differentiated thyroid cancer in patients whose disease progressed …

    Published on 3/23/2015
  • Exact Sciences, Aetna sales and marketing update

    Exact Sciences Corp. (NASDAQ:EXAS), Madison, Wis. Aetna Inc. (NYSE:AET), Hartford, Conn. Business: Cancer Aetna will cover Exacts Cologuard to diagnose colon cancer, effective for three years starting April 1. Cologuard…

    Published on 3/23/2015
  • Vertex sales and marketing update

    Vertex Pharmaceuticals Inc. (NASDAQ:VRTX), Boston, Mass. Business: Pulmonary On Dec. 1, 2014, Vertexs Kalydeco ivacaftor was listed on the Australian Pharmaceutical Benefits Scheme (PBS) under a pay for performance …

    Published on 3/23/2015
  • Chugai sales and marketing update

    Chugai Pharmaceutical Co. Ltd. (Tokyo:4519), Tokyo, Japan Business: Cancer Chugai launched Zelboraf vemurafenib in Japan to treat unresectable melanoma with a BRAF mutation. The mutation is identified using the cobas …

    Published on 3/16/2015
  • Eisai sales and marketing update

    Eisai Co. Ltd. (Tokyo:4523), Tokyo, Japan Business: Cancer Eisai said the Cancer Drugs Fund (CDF) panel upheld an appeal from the company to reconsider a January decision from NHS England to remove breast cancer drug …

    Published on 3/16/2015
  • Meridian Bioscience sales and marketing update

    Meridian Bioscience Inc. (NASDAQ:VIVO), Cincinnati, Ohio Business: Diagnostic Meridian launched the TRU Strep Pneumo assay in Europe, the Middle East and Africa to detect Streptococcus pneumoniae in urine and …

    Published on 3/16/2015
  • Otsuka Pharmaceutical, Takeda sales and marketing update

    Otsuka Pharmaceutical Co. Ltd., Tokyo, Japan Takeda Pharmaceutical Co. Ltd. (Tokyo:4502), Osaka, Japan Business: Gastrointestinal Takeda and Otsuka launched Takecab vonoprazan fumarate in Japan to treat acid-related …

    Published on 3/16/2015
  • CombiMatrix, Fortified Provider Network sales and marketing update

    CombiMatrix Corp. (NASDAQ:CBMX), Irvine, Calif. Fortified Provider Network Inc., Scottsdale, Ariz. Business: Diagnostic Fortified Provider Network (FPN) will cover CombiMatrixs diagnostic laboratory services. FPN has …

    Published on 3/9/2015
  • Ferring sales and marketing update

    Ferring Pharmaceuticals A/S, Saint-Prex, Switzerland Business: Autoimmune Ferring launched Cortiment MMX budesonide in Europe to treat adults with active mild to moderate ulcerative colitis in cases where mesalazine has…

    Published on 3/9/2015
  • Intas Pharmaceuticals sales and marketing update

    Intas Pharmaceuticals Ltd., Ahmedabad, India Business: Hematology, Biosimilars Intas Accord Healthcare subsidiary launched Accofil, a biosimilar of neutropenia drug Neupogen filgrastim, in the EU. Filgrastim is a …

    Published on 3/9/2015
  • Pacira sales and marketing update

    Pacira Pharmaceuticals Inc. (NASDAQ:PCRX), Parsippany, N.J. Business: Neurology Pacira said it resolved a warning letter from FDAs Office of Prescription Drug Promotion dated Sept. 25, 2014, regarding educational …

    Published on 3/9/2015
  • Raptor, Clinigen Group sales and marketing update

    Raptor Pharmaceutical Corp. (NASDAQ:RPTP), Novato, Calif. Clinigen Group plc (LSE:CLIN), Burton-on-Trent, U.K. Business: Renal Clinigen launched an international global access program outside of the U.S., Latin America …

    Published on 3/9/2015

< Previous   1  2  3  4  5  6  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993